VAXX stock at $0.0001 intraday on 11 Feb 2026: critical risks for NASDAQ holders

VAXX stock dropped to $0.0001 intraday on 11 Feb 2026, an intraday fall of -99.42% from yesterday’s close. Trading volume was 452 shares versus a 50-day average of 16,969, and market capitalization sits at $2,187,036.00 USD on the NASDAQ in the United States. The move follows thin liquidity and continued negative fundamentals, with trailing EPS at -0.45 and a negative PE metric. We examine price drivers, clinical and balance-sheet context, and technicals for active traders and long-term investors.

Intraday price action for VAXX stock

VAXX stock opened at $0.01725 and hit a low of $0.0001 during intraday trading on 11 Feb 2026, recording a one-day change of -0.01715 or -99.42%. Volume was 452 shares, well below the average of 16,969, signaling extremely low liquidity that magnified the price swing. The year high remains $0.05 and year low $0.0001, indicating a volatile trading range for this NASDAQ-listed biotechnology name.

Valuation and financial snapshot of Vaxxinity, Inc. (VAXX)

Vaxxinity, Inc. (VAXX) shows a market cap of $2,187,036.00 USD and shares outstanding at 126,784,680. Key metrics: EPS -0.45, PB ratio 0.16, current ratio 1.89, and debt to equity 1.13, underscoring negative earnings and a leveraged balance sheet. Enterprise value of $12,424,036.00 USD versus limited revenue highlights valuation dominated by development-stage assets rather than steady cash flows.

Clinical pipeline, catalysts and VAXX news linkage

Vaxxinity develops vaccine and neurodegenerative candidates including UB-611 (COVID-19, phase 3), UB-311 (Alzheimer’s, phase 2) and UB-312 (Parkinson’s, phase 1). Clinical readouts or trial updates are the primary catalysts that could move the VAXX stock given the lack of commercial revenue. Investors should watch the company’s scheduled earnings announcement on 2026-03-26 and any clinical data releases for immediate market impact.

Technicals, liquidity and trading risks for VAXX stock

Technical indicators show an RSI near 53.27 and ADX 52.46, but volume-based measures reveal weak liquidity (on‑book volume and OBV negative). The stock’s 50-day average price is $0.00381 and 200-day average $0.00822, so the current print is far below moving averages. Thin trading increases execution risk and widens spreads, meaning intraday moves can be driven more by order size than fundamentals.

Meyka AI rates VAXX and model forecast

Meyka AI rates VAXX with a score out of 100: 61.47 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a short-term reference target of $0.00100 USD for VAXX, versus the current $0.00010 USD, implying an estimated upside of 900.00%, but forecasts are model-based projections and not guarantees.

Sector context and primary risks for VAXX investors

Vaxxinity operates in the Healthcare sector and Biotechnology industry where clinical binary risk is high and sector peers show greater liquidity and revenue backing. Primary risks: continued negative EPS, high debt relative to market cap, and sparse trading liquidity. Opportunities depend on positive clinical readouts, partnership deals, or equity raises that materially change funding and outlook.

Final Thoughts

VAXX stock’s intraday print of $0.0001 USD on 11 Feb 2026 reflects acute liquidity stress and ongoing fundamental challenges for Vaxxinity, Inc. The company carries negative trailing EPS (-0.45) and a modest cash buffer per share ($0.24026), while enterprise value sits near $12,424,036.00 USD, indicating investor caution. Our Meyka AI forecast model projects $0.00100 USD, an implied upside of 900.00% from the current price, but that scenario depends on meaningful clinical or financing catalysts. Traders should treat VAXX as a highly speculative NASDAQ microcap with execution risk, and long-term investors should seek evidence of improved cash runway or successful clinical data before increasing exposure. Meyka AI-powered market analysis highlights the priority: monitor the 2026-03-26 earnings announcement, trial milestones, and any equity financing that would alter dilution and liquidity dynamics. Forecasts are model-based projections and not guarantees, and this analysis is informational, not financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.